Navigation Links
Biomerix Corporation and Gel Company Announce Strategic Distribution Agreement
Date:7/19/2011

FREMONT, Calif., July 19, 2011 /PRNewswire/ -- Biomerix Corporation and Gel Company today announced a strategic distribution agreement for the Biomerix 3D Scaffold, a novel three-dimensional tissue scaffold. Under the agreement, Gel Company will market and distribute the Biomerix 3D Scaffold to researchers in the life science community across the United States.

The Biomerix 3D Scaffold consists of a non-degradable, open-cell polycarbonate polyurethane, designed to mimic the nature and function of the extracellular matrix (ECM). Its unique three-dimensional microarchitecture embodies a network of interconnecting cells and pores constructed to support tissue ingrowth, allowing researchers to study cells in an environment that simulates the conditions of cells in the body.  The unique chemistry and macroporous structure of the Biomerix 3D Scaffold supports the growth of myriad cell types and delivers more predictive results compared to standard 2D cell culture systems.  The proprietary Biomerix Biomaterial, used to manufacture the Biomerix 3D Scaffold has been demonstrated to support optimal cell proliferation and superior cell viability in both in-vitro and in-vivo studies and has received seven US and international regulatory clearances for a variety of indications.

"We have already experienced interest in the Biomerix 3D Scaffold, and we are delighted to add this innovative technology to our portfolio of products," said Greg Richardson, President of the Gel Company. "The Biomerix 3D Scaffold is an excellent fit with our expertise in the life science research community."

"Biomerix is very pleased to have the Gel Company become one of our distribution partners.  Their reputation as a quality supplier, as well as their commitment to customer service, was appealing to Biomerix," stated Kenneth Hayes, President and Chief Executive Officer of Biomerix Corporation.  "We look forward to a long and prosperous partnership with the Gel Company."

About Biomerix Corporation

Biomerix Corporation is recognized as a leader in the development and manufacturing of innovative non-absorbable and bioresorbable three-dimensional, open-cell, resilient elastomeric polyurethane biomaterials.  The Company's expertise includes the development, co-development and supply of new proprietary materials, products and components to customers in the medical, industrial and consumer industry markets.

For more information please visit www.biomerix.com or call 888.308.3620.

About Gel Company

Gel Company develops, manufactures and supplies innovative tools for Proteomics, Genomics, Cell Biology, Liquid Handling and Microarray to scientists around the world.  We provide products with superior performance that are simple, safe to use and that are environmentally friendly.  The company has a team of experienced scientists dedicated to developing new technologies and products as well as providing the highest level of customer support.

For more information please visit www.gelcompany.com.


'/>"/>
SOURCE Biomerix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biomerix Awarded Two Device Licenses by Health Canada
2. Biomerix Granted CE Mark for its REVIVE™ Soft Tissue Repair Mesh
3. Biomerix Ventral Hernia Repair Mesh Receives FDA 510(k) Clearance
4. Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011
5. QuantRx Biomedical Corporation Provides Corporate Update
6. American Scientific Resources and School Health Corporation to Supply The Disintegrator™ Needle Destruction Device to Texas School District
7. China Medicine Corporation to Restate Financial Statements for 2006 and 2007
8. CVS Caremark Corporation Announces Quarterly Dividend
9. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
10. Curaxis Pharmaceutical Corporation Announces Key Changes to Its Board of Directors and Management Team in Progression Toward Clinical Trials
11. Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):